Table 3.

Urinary concentrations of BPA in 50 Ex-R adults over a six-week monitoring period^a.

Sample typeb,c,d	Nf	GM (GSD)g	Min.	Percentiles						Max.
				5th	25th	50th	75th	95th	99th
FMVe
ng/mL	294	1.83 (3.17)	<	0.22	0.98	1.75	3.88	9.30	44.0	81.5
ng/mL-SG	293	1.67 (3.40)	<	0.18	0.86	1.63	3.29	14.3	48.1	141
ng/mg	293	1.63 (3.62)	<	0.17	0.83	1.64	3.41	15.2	58.3	133
ng/min	291	1.35 (3.63)	<	0.13	0.63	1.38	2.81	12.6	56.6	134
Bedtime void
ng/mL	289	1.79 (3.26)	<	0.18	0.96	2.04	3.66	10.2	20.5	38.2
ng/mL-SG	287	1.67 (4.11)	<	0.13	0.73	1.87	3.70	18.4	40.5	94.9
ng/mg	287	1.78 (4.53)	<	0.12	0.77	1.89	4.24	23.6	63.9	162
ng/min	284	1.71 (4.44)	<	0.12	0.73	1.72	4.53	19.4	75.3	96.7
24-h sample
ng/mL	1886	2.00 (3.41)	<	0.23	1.00	2.12	4.20	12.6	35.9	1021
ng/mL-SG	1866	2.39 (4.06)	<	0.24	1.03	2.41	5.21	24.8	88.6	2100
ng/mg	1866	2.65 (4.56)	<	0.24	1.03	2.57	6.35	31.3	128	3262
ng/min	1875	2.70 (4.53)	<	0.24	1.03	2.67	6.66	31.5	122	2832
All
ng/mL	2477	1.96 (3.36)	<	0.22	0.99	2.07	4.12	12.2	34.7	1021
ng/mL-SG	2453	2.19 (4.01)	<	0.21	0.99	2.20	4.73	23.3	73.6	2100
ng/mg	2453	2.38 (4.48)	<	0.20	0.97	2.29	5.70	28.0	102	3262
ng/min	2457	2.36 (4.49)	<	0.20	0.94	2.31	5.85	28.1	96.3	2832

^aUrine data are presented as unadjusted (ng/mL) and as specific-gravity (ng/mL-SG), creatinine (ng/mg), and excretion rate (ng/min) adjusted values.

^bBPA was detected in 98%, 97%, and 98% of the FMV, bedtime, and 24-h urine samples, respectively.

^c18 urine samples were excluded because they failed our quality control standards.

^d6 urine samples were not analyzed for BPA levels due to laboratory error.

^eFMV (first-morning void).

^fNumber of urine samples.

^gGeometric mean and geometric standard deviation.